We conducted an observational study in the setting of a prospective cohort of patients attending the Vitiligo Clinic at the Department of Dermatology, University Hospital Center of Bordeaux, Bordeaux, France, between January 1, 2006, and July 1, 2010. The study was approved by the local ethics committee of the University Hospital of Bordeaux, France. All the patients with a diagnosis of NSV were enrolled in the present study. Nonsegmental vitiligo was defined as an acquired progressive bilateral hypomelanosis according to the Vitiligo European Task Force (VETF) definition.8 Mixed vitiligo, that is, the association of a characteristic segmental involvement associated usually in a second step with the onset of bilateral vitiligo patches,9 and other forms of vitiligo (segmental, focal, mucosal, and not classifiable) were excluded. The VETF questionnaires were completed for each patient attending the clinic at the first visit.8 The VETF form provides a wide range of demographic and clinical information, including sex, age, age at onset of leukoderma, phototype, site of involvement and distribution patterns, Koebner phenomenon (defined as depigmentation on scars), presence of HNs, family history of vitiligo, personal or family history of chronic autoimmune/autoinflammatory diseases (autoimmune thyroiditis, atopic dermatitis, psoriasis, rheumatoid arthritis, type 1 diabetes mellitus, alopecia areata, sarcoidosis, systemic lupus erythematosus, Addison disease, and Crohn disease), family history of premature hair graying (PHG) (>50% white hair before age 40 years) with family trees if needed, emotional stress at onset, and response to treatment, if any. Finally, staging and spreading were assessed as recommended by the VETF group after natural light and Wood lamp examination.9 This evaluation individually assesses 5 body regions (head and neck, trunk, upper and lower extremities, hands, and feet) for (1) extent of disease (affected body surface, percentage scored 0% to 100%), (2) stage of disease (staging) (normal pigmentation/incomplete depigmentation/complete depigmentation/complete depigmentation plus partial leukotrichia/complete depigmentation plus complete leukotrichia) (scored 0-4), and (3) disease progression (spreading) (regressive is scored –1; stable, or 0; progressive, 1). A total score for staging and spreading was determined, with values ranging from 0 to 16 for staging and from –5 to 5 for spreading.